| Literature DB >> 30896814 |
Abstract
Human adipose tissue‑derived stromal stem cells (HASCs) represent a promising regenerative resource for breast reconstruction and augmentation. However, the mechanisms involved in inducing its adipogenic differentiation remain to be fully elucidated. The present study aimed to comprehensively investigate the expression changes in mRNAs, microRNAs (miRNAs) and long non‑coding (lnc)RNAs during the adipogenic differentiation of HASCs, and screen crucial lncRNA‑miRNA‑mRNA interaction axes using microarray datasets GSE57593, GSE25715 and GSE61302 collected from the Gene Expression Omnibus database. Following pretreatment, differentially expressed genes (DEGs), miRNAs (DE‑miRNAs) or lncRNAs (DE‑lncRNAs) between undifferentiated and differentiated HASCs were identified using the Linear Models for Microarray data method. A protein‑protein interaction (PPI) network was constructed for the DEGs based on protein databases, followed by module analysis. The 'lncRNA‑miRNA‑mRNA' competing endogenous RNA (ceRNA) network was constructed based on the interactions between miRNAs and mRNAs, lncRNAs and miRNAs predicted by the miRWalk and lnCeDB databases. The underlying functions of mRNAs were predicted using the clusterProfiler package. In the present study, 905 DEGs, 36 DE‑miRNAs and 577 DE‑lncRNAs were screened between undifferentiated HASCs and differentiated adipocyte cells. PPI network analysis demonstrated that LEP may be a hub gene, which was also enriched in significant module 5. LEP was predicted to be involved in the Janus kinase‑signal transducer and activator of transcription signaling pathway, and the regulation of inflammatory response. The upregulation of LEP was regulated by downregulated hsa‑miRNA (miR)‑130b‑5p and hsa‑miR‑23a‑5p (or hsa‑miR‑302d‑3p). These miRNAs also respectively interacted with RP11‑552F3.9 (or RP11‑15A1.7), ultimately forming the ceRNA axes. In conclusion, the present study revealed that the RP11‑552F3.9 (RP11‑15A1.7)‑hsa‑miR‑130b‑5p/hsa‑miR‑23a‑5p (hsa‑miR‑302d‑3p)‑LEP interaction axes may be crucial for inducing the adipogenic differentiation of HASCs via involvement in inflammation.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30896814 PMCID: PMC6471198 DOI: 10.3892/mmr.2019.10067
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Top 10 upregulated and downregulated differentially expressed lncRNAs, miRNAs and mRNAs.
| lncRNAs | mRNAs | miRNAs | ||||||
|---|---|---|---|---|---|---|---|---|
| lncRNA | logFC | Adjusted P-value | miRNA | logFC | P-value | mRNA | logFC | Adjusted P-value |
| ZBED3-AS1 | 4.74 | 2.74×10−7 | hsa-miR-29b-2* | 2.89 | 3.08×10−5 | FGF11 | 2.14 | 3.54×10−7 |
| RP11-95P13.1 | 4.95 | 5.72×10−7 | hsa-miR-642a-3p | 5.28 | 4.29×10−4 | DDIT4L | 3.38 | 4.11×10−7 |
| AC104654.2 | 4.12 | 1.08×10−5 | hsa-miR-2114 | 2.80 | 1.31×10−3 | PKP2 | 1.74 | 4.11×10−7 |
| RP11-196G18.3 | 2.19 | 1.41×10−5 | hsa-miR-30a* | 2.54 | 2.20×10−3 | GPR155 | 1.57 | 4.11×10−7 |
| RP11-439A17.9 | 2.19 | 1.41×10−5 | hsa-miR-34b* | 4.57 | 3.85×10−3 | ZNF582-AS1 | 1.20 | 4.11×10−7 |
| RP5-998N21.4 | 2.19 | 1.41×10−5 | hsa-miR-668 | 2.29 | 4.38×10−3 | PGRMC1 | 1.10 | 4.11×10−7 |
| CTC-564N23.2 | 4.65 | 2.62×10−5 | hsa-miR-345 | 1.81 | 4.20×10−3 | ZNF436-AS1 | 2.26 | 5.34×10−7 |
| CHL1-AS1 | 3.53 | 5.17×10−5 | hsa-miR-675* | 2.60 | 5.68×10−3 | FAM162A | 1.14 | 5.34×10−7 |
| AC104653.1 | 2.94 | 5.17×10−5 | hsa-miR-34a | 3.54 | 8.48×10−3 | BNIP3 | 1.23 | 1.44×10−6 |
| RP11-696N14.1 | 2.15 | 5.17×10−5 | hsa-miR-378c | 3.10 | 9.65×10−3 | IGFBP5 | 1.74 | 1.85×10−6 |
| LINC01085 | −4.82 | 1.20×10−7 | hsa-miR-485-3p | −3.30 | 9.05×10−4 | FOSB | −6.71 | 1.28×10−14 |
| APCDD1L-AS1 | −3.14 | 2.45×10−6 | hsa-miR-3151 | −2.15 | 1.80×10−3 | IER2 | −1.72 | 2.51×10−9 |
| RP11-54A9.1 | −3.45 | 5.73×10−6 | hsa-miR-130b* | −1.42 | 6.82×10−3 | KLF2 | −2.02 | 3.82×10−9 |
| CTD-2354A18.1 | −3.16 | 7.55×10−6 | hsa-miR-302d | −1.66 | 8.82×10−3 | ID1 | −4.29 | 1.64×10−8 |
| CTD-2066L21.2 | −5.09 | 1.11×10−5 | hsa-miR-487a | −2.39 | 7.82×10−3 | SKIL | −1.49 | 4.79×10−8 |
| RP11-114H23.1 | −1.83 | 1.11×10−5 | hsa-miR-411* | −1.31 | 4.96×10−2 | PRIMA1 | −2.89 | 9.17×10−8 |
| RP3-410C9.2 | −5.035 | 1.30×10−5 | hsa-miR-154* | −2.12 | 1.72×10−2 | RRM2 | −4.51 | 9.17×10−8 |
| APOBEC3B-AS1 | −3.97 | 1.30×10−5 | hsa-let-7e | −1.35 | 2.81×10−3 | EGR3 | −5.27 | 9.17×10−8 |
| RP11-30P6.6 | −3.10 | 1.41×10−5 | hsa-miR-125b-1* | −1.54 | 2.84×10−2 | C16orf89 | −2.88 | 1.73×10−7 |
| LINC00460 | −3.07 | 2.39×10−5 | hsa-miR-23b | −1.03 | 4.18×10−2 | NFKBIZ | −1.84 | 2.89×10−7 |
lncRNA, long non-coding RNA; miRNA, microRNA.
Figure 1.Hierarchical clustering and heatmap analysis of differentially expressed (A) genes, (B) microRNAs and (C) long non-coding RNAs. Red, high expression; blue, low expression.
Figure 2.Protein-protein interaction network. Pink nodes, upregulated genes; light blue nodes, downregulated genes; brown line/edges, interaction between genes. A larger size of a node (protein) indicates it has a higher degree (number of interactions).
Topological features of DEGs in the protein-protein interaction network.
| DEG | Degree | DEG | Betweenness | DEG | Closeness | Overlapped | Expression |
|---|---|---|---|---|---|---|---|
| JUN | 52 | JUN | 31682.11 | JUN | 0.12 | JUN | Down |
| CCNB1 | 40 | EHHADH | 14484.48 | PTPRC | 0.12 | CCNB1 | Down |
| CXCL10 | 33 | RAC2 | 9452.98 | ENO2 | 0.12 | CXCL10 | Up |
| CCNB2 | 32 | CCNB1 | 9055.00 | CCNB1 | 0.12 | ENO2 | Up |
| AURKA | 31 | TAC1 | 8899.64 | RAC2 | 0.12 | EHHADH | Up |
| KIF11 | 31 | ENO2 | 8383.99 | KDR | 0.12 | PTPRC | Down |
| ENO2 | 30 | KDR | 7498.68 | VIM | 0.12 | RAC2 | Down |
| KIF2C | 30 | PTPRC | 6640.64 | EHHADH | 0.12 | LEP | UP |
| EHHADH | 29 | PRKAR2B | 6288.09 | HPGDS | 0.12 | KDR | Down |
| PTPRC | 28 | THBS1 | 5735.04 | MCL1 | 0.12 | ITGAM | Down |
| HADH | 28 | VIM | 4843.88 | TAC1 | 0.12 | ITGAX | Down |
| RAC2 | 27 | LEP | 4442.09 | CXCL10 | 0.11 | CXCR4 | Down |
| CXCR4 | 27 | CXCL10 | 4424.07 | MGP | 0.11 | HADH | Up |
| EZH2 | 27 | HADH | 4155.38 | CXCR4 | 0.11 | MGP | Down |
| MCM2 | 25 | MGP | 3982.14 | LEP | 0.11 | TAC1 | Down |
| PLK4 | 24 | HPGDS | 3752.53 | BMP2 | 0.11 | ||
| CENPF | 24 | CNR1 | 3700.56 | PTPRF | 0.11 | ||
| CDCA8 | 24 | PRKG2 | 3608.14 | ADIPOQ | 0.11 | ||
| LEP | 23 | CALB2 | 3569.40 | WNT5A | 0.11 | ||
| ITGAX | 23 | WNT5A | 3556.75 | ACE | 0.11 | ||
| CXCL11 | 23 | ITGAX | 3251.43 | ITGAM | 0.11 | ||
| BLM | 23 | AK4 | 3154.06 | THBS1 | 0.11 | ||
| KIF15 | 23 | TUBA4A | 2982.07 | NES | 0.11 | ||
| CDT1 | 23 | HMOX1 | 2856.41 | CPT1A | 0.11 | ||
| KDR | 22 | PTPRF | 2836.38 | PLIN1 | 0.11 | ||
| MGP | 22 | ADIPOQ | 2766.04 | CX3CL1 | 0.11 | ||
| CCL28 | 22 | ITGAM | 2744.81 | BTK | 0.11 | ||
| HJURP | 22 | CXCR4 | 2674.93 | MAP2K6 | 0.11 | ||
| TAC1 | 21 | ITGA7 | 2632.36 | CXCL2 | 0.11 | ||
| ITGAM | 21 | BMP2 | 2624.89 | CXCL1 | 0.11 | ||
| CXCL2 | 21 | PLIN1 | 2616.07 | CALB2 | 0.11 | ||
| CXCL1 | 21 | ACE | 2575.42 | ITGAX | 0.11 | ||
| TUBA4A | 20 | ITGB2 | 2559.34 | HADH | 0.11 | ||
| MCM5 | 20 | ALDH3A2 | 2510.02 | IRF1 | 0.11 | ||
| MCL1 | 19 | RRAD | 2504.60 | CCL28 | 0.11 |
DEG, differentially expressed gene.
Figure 3.Significant modules extracted from the protein-protein interaction network. (A) Module 1; (B) module 2; (C) module 3; (D) module 4; (E) module 5; (F) module 6.
Module analysis results.
| Cluster | Score[ | Nodes (n) | Edges (n) | Node IDs |
|---|---|---|---|---|
| 1 | 17.89 | 19 | 161 | HELLS, EZH2, HJURP, CDT1, CENPF, MCM2, POLE2, FAM64A, SPAG5, KIF2C, BLM, PLK4, CDCA8, KIF14, AURKA, KIF11, KIF15, CCNB1, CCNB2 |
| 2 | 13.00 | 13 | 78 | CXCL10, GAL, CXCL5, CXCL11, C5, P2RY12, CCL28, CNR1, S1PR1, CXCL2, CXCL1, CXCR4, CXCL6 |
| 3 | 9.78 | 10 | 44 | GEN1, COMP, HADH, PTPRF, HRASLS5, ENO2, MCL1, MGP, EREG, NES |
| 4 | 7.00 | 21 | 70 | OAS1, JUN, GNRHR2, AVPR1A, P2RY1, ITGAM, CCL22, HERC5, EDNRB, OASL, PTGFR, IFIH1, PTPRC, IRF7, IFI44, HTR2A, ITGAX, TAC1, IFI6, NMB, HTR2B |
| 5 | 4.67 | 10 | 21 | ACSL1, SCD, DGAT2, PNPLA2, LEP, CIDEC, IL4R, IL10RA, TSLP, FABP4 |
| 6 | 4.36 | 12 | 24 | TUBA1A, PRKAR2B, ABAT, EHHADH, ALDH3A2, TUBD1, ALDH1B1, MAPRE3, PECR, PDHX, TUBA4A, HSD11B1 |
| 7 | 3.33 | 4 | 5 | PDE2A, PRELP, RRAD, LRRC2 |
| 8 | 3.13 | 17 | 25 | MMRN1, ANK2, ATP1A2, NRCAM, VIM, KDR, ATP1A1, PLOD2, TIMP3, COL8A2, COL4A4, CALB2, PLN, KCNQ3, A2M, COL18A1, SCN2A |
| 9 | 3.00 | 3 | 3 | HIST1H3C, HIST1H2AC, HIST1H2BD |
| 10 | 3.00 | 3 | 3 | HSD17B14, ADH4, TP53I3 |
| 11 | 3.00 | 3 | 3 | TRIM69, RNF19B, TRIM9 |
| 12 | 3.00 | 3 | 3 | GPAT2, AGPAT5, GPD1 |
| 13 | 3.00 | 3 | 3 | VLDLR, DAB1, MAP1B |
| 14 | 3.00 | 3 | 3 | LAMB3, ITGA7, LAMA2 |
Score = density × number of nodes.
Kyoto Encyclopedia of Genes and Genomes pathway enrichment for genes in modules.
| Cluster | ID | Description | Adjusted P-value | Genes |
|---|---|---|---|---|
| 1 | hsa04914 | Progesterone-mediated oocyte maturation | 1.16×10−3 | AURKA/CCNB1/CCNB2 |
| 1 | hsa04110 | Cell cycle | 1.16×10−3 | MCM2/CCNB1/CCNB2 |
| 1 | hsa04114 | Oocyte meiosis | 1.16×10−3 | AURKA/CCNB1/CCNB2 |
| 1 | hsa04068 | FoxO signaling pathway | 1.16×10−3 | PLK4/CCNB1/CCNB2 |
| 1 | hsa03030 | DNA replication | 2.02×10−3 | MCM2/POLE2 |
| 1 | hsa04115 | p53 signaling pathway | 5.99×10−3 | CCNB1/CCNB2 |
| 1 | hsa04218 | Cellular senescence | 2.73×10−2 | CCNB1/CCNB2 |
| 2 | hsa04062 | Chemokine signaling pathway | 1.96×10−9 | CXCL10/CXCL5/CXCL11/CCL28/CXCL2/CXCL1/CXCR4/CXCL6 |
| 2 | hsa04060 | Cytokine-cytokine receptor interaction | 2.03×10−8 | CXCL10/CXCL5/CXCL11/CCL28/CXCL2/CXCL1/CXCR4/CXCL6 |
| 2 | hsa04657 | IL-17 signaling pathway | 2.28×10−6 | CXCL10/CXCL5/CXCL2/CXCL1/CXCL6 |
| 2 | hsa04668 | TNF signaling pathway | 1.60×10−4 | CXCL10/CXCL5/CXCL2/CXCL1 |
| 2 | hsa05133 | Pertussis | 1.41×10−3 | CXCL5/C5/CXCL6 |
| 2 | hsa05323 | Rheumatoid arthritis | 1.94×10−3 | CXCL5/CXCL1/CXCL6 |
| 2 | hsa04672 | Intestinal immune network for IgA production | 1.28×10−2 | CCL28/CXCR4 |
| 2 | hsa05134 | Legionellosis | 1.41×10−2 | CXCL2/CXCL1 |
| 2 | hsa05132 | Salmonella infection | 0.02.99×10−2 | CXCL2/CXCL1 |
| 2 | hsa04620 | Toll-like receptor signaling pathway | 3.88×10−2 | CXCL10/CXCL11 |
| 4 | hsa04080 | Neuroactive ligand-receptor interaction | 7.99×10−4 | AVPR1A/P2RY1/EDNRB/PTGFR/HTR2A/HTR2B |
| 4 | hsa04020 | Calcium signaling pathway | 8.35×10−4 | AVPR1A/EDNRB/PTGFR/HTR2A/HTR2B |
| 4 | hsa05164 | Influenza A | 8.30×10−3 | OAS1/JUN/IFIH1/IRF7 |
| 4 | hsa05168 | Herpes simplex infection | 8.30×10−3 | OAS1/JUN/IFIH1/IRF7 |
| 4 | hsa05162 | Measles | 3.60×10−2 | OAS1/IFIH1/IRF7 |
| 4 | hsa05161 | Hepatitis B | 3.68×10−2 | JUN/IFIH1/IRF7 |
| 4 | hsa04621 | NOD-like receptor signaling pathway | 4.88×10−2 | OAS1/JUN/IRF7 |
| 5 | hsa04630 | Jak-STAT signaling pathway | 6.39×10−4 | LEP/IL4R/IL10RA/TSLP |
| 5 | hsa03320 | PPAR signaling pathway | 8.88×10−4 | ACSL1/SCD/FABP4 |
| 5 | hsa04060 | Cytokine-cytokine receptor interaction | 1.57×10−3 | LEP/IL4R/IL10RA/TSLP |
| 5 | hsa01212 | Fatty acid metabolism | 9.00×10−3 | ACSL1/SCD |
| 5 | hsa04923 | Regulation of lipolysis in adipocytes | 9.10×10−3 | PNPLA2/FABP4 |
| 5 | hsa00561 | Glycerolipid metabolism | 9.65×10−3 | DGAT2/PNPLA2 |
| 5 | hsa04920 | Adipocytokine signaling pathway | 0.01.06×10−2 | ACSL1/LEP |
| 5 | hsa04152 | AMPK signaling pathway | 2.76×10−2 | SCD/LEP |
| 5 | hsa00061 | Fatty acid biosynthesis | 4.36×10−2 | ACSL1 |
| 6 | hsa00410 | β-alanine metabolism | 1.50×10−6 | ABAT/EHHADH/ALDH3A2/ALDH1B1 |
| 6 | hsa00280 | Valine, leucine and isoleucine degradation | 4.60×10−6 | ABAT/EHHADH/ALDH3A2/ALDH1B1 |
| 6 | hsa00380 | Tryptophan metabolism | 1.65×10−4 | EHHADH/ALDH3A2/ALDH1B1 |
| 6 | hsa00071 | Fatty acid degradation | 1.66×10−4 | EHHADH/ALDH3A2/ALDH1B1 |
| 6 | hsa00310 | Lysine degradation | 3.22×10−4 | EHHADH/ALDH3A2/ALDH1B1 |
| 6 | hsa00340 | Histidine metabolism | 1.98×10−3 | ALDH3A2/ALDH1B1 |
| 6 | hsa00053 | Ascorbate and aldarate metabolism | 2.21×10−3 | ALDH3A2/ALDH1B1 |
| 6 | hsa00650 | Butanoate metabolism | 2.21×10−3 | ABAT/EHHADH |
| 6 | hsa00640 | Propanoate metabolism | 2.57×10−3 | ABAT/EHHADH |
| 6 | hsa00620 | Pyruvate metabolism | 3.44×10−3 | ALDH3A2/ALDH1B1 |
| 6 | hsa01212 | Fatty acid metabolism | 4.70×10−3 | EHHADH/PECR |
| 6 | hsa00330 | Arginine and proline metabolism | 4.70×10−3 | ALDH3A2/ALDH1B1 |
| 6 | hsa05130 | Pathogenic | 5.24×10−3 | TUBA1A/TUBA4A |
| 6 | hsa00561 | Glycerolipid metabolism | 6.00×10−3 | ALDH3A2/ALDH1B1 |
| 6 | hsa00010 | Glycolysis/Gluconeogenesis | 6.90×10−3 | ALDH3A2/ALDH1B1 |
| 6 | hsa04146 | Peroxisome | 9.55×10−3 | EHHADH/PECR |
| 6 | hsa04540 | Gap junction | 1.01×10−2 | TUBA1A/TUBA4A |
| 6 | hsa04210 | Apoptosis | 2.27×10−2 | TUBA1A/TUBA4A |
| 6 | hsa04145 | Phagosome | 2.58×10−2 | TUBA1A/TUBA4A |
| 6 | hsa04530 | Tight junction | 3.03×10−2 | TUBA1A/TUBA4A |
| 6 | hsa01040 | Biosynthesis of unsaturated fatty acids | 4.23×10−2 | PECR |
Figure 4.Pathway and GO term enrichment of gene clusters. (A) Kyoto Encyclopedia of Genes and Genomes pathway and (B) GO term enrichment analyses for genes of significant modules. The values within brackets are the number of genes enriched. GO, Gene Ontology.
GO enrichment for genes in modules.
| Cluster | ID | Description | Adjusted P-value | Genes |
|---|---|---|---|---|
| 1 | GO:0051310 | Metaphase plate congression | 4.09×10−11 | CDT1/CENPF/SPAG5/KIF2C/CDCA8/KIF14/CCNB1 |
| 1 | GO:0051303 | Establishment of chromosome localization | 1.45×10−10 | CDT1/CENPF/SPAG5/KIF2C/CDCA8/KIF14/CCNB1 |
| 1 | GO:0050000 | Chromosome localization | 1.45×10−10 | CDT1/CENPF/SPAG5/KIF2C/CDCA8/KIF14/CCNB1 |
| 1 | GO:0140014 | Mitotic nuclear division | 1.71×10−10 | CDT1/CENPF/SPAG5/KIF2C/CDCA8/KIF14/AURKA/KIF11/CCNB1 |
| 1 | GO:0000280 | Nuclear division | 5.46×10−9 | CDT1/CENPF/SPAG5/KIF2C/CDCA8/KIF14/AURKA/KIF11/CCNB1 |
| 2 | GO:0060326 | Cell chemotaxis | 9.21×10−14 | CXCL10/CXCL5/CXCL11/C5/CCL28/S1PR1/CXCL2/CXCL1/CXCR4/CXCL6 |
| 2 | GO:0050900 | Leukocyte migration | 9.21×10−14 | CXCL10/CXCL5/CXCL11/C5/P2RY12/CCL28/S1PR1/CXCL2/CXCL1/CXCR4/CXCL6 |
| 2 | GO:0002685 | Regulation of leukocyte migration | 9.21×10−14 | CXCL10/CXCL5/CXCL11/C5/P2RY12/CCL28/CXCL2/CXCL1/CXCL6 |
| 2 | GO:0050920 | Regulation of chemotaxis | 1.35×10−13 | CXCL10/CXCL5/CXCL11/C5/S1PR1/CXCL2/CXCL1/CXCR4/CXCL6 |
| 2 | GO:0030595 | Leukocyte chemotaxis | 2.66×10−13 | CXCL10/CXCL5/CXCL11/C5/S1PR1/CXCL2/CXCL1/CXCR4/CXCL6 |
| 4 | GO:0007204 | Positive regulation of cytosolic calcium ion concentration | 6.33×10−7 | AVPR1A/P2RY1/EDNRB/PTPRC/HTR2A/TAC1/NMB/HTR2B |
| 4 | GO:0009615 | Response to virus | 6.33×10−7 | OAS1/CCL22/HERC5/OASL/IFIH1/PTPRC/IRF7/IFI44 |
| 4 | GO:0051480 | Regulation of cytosolic calcium ion concentration | 6.33×10−7 | AVPR1A/P2RY1/EDNRB/PTPRC/HTR2A/TAC1/NMB/HTR2B |
| 4 | GO:2000021 | Regulation of ion homeostasis | 8.55×10−7 | AVPR1A/EDNRB/PTPRC/HTR2A/TAC1/IFI6/HTR2B |
| 4 | GO:0007620 | Copulation | 1.45×10−6 | AVPR1A/P2RY1/EDNRB/TAC1 |
| 5 | GO:0006641 | Triglyceride metabolic process | 8.23×10−5 | ACSL1/DGAT2/PNPLA2/FABP4 |
| 5 | GO:0006639 | Acylglycerol metabolic process | 8.23×10−5 | ACSL1/DGAT2/PNPLA2/FABP4 |
| 5 | GO:0006638 | Neutral lipid metabolic process | 8.23×10−5 | ACSL1/DGAT2/PNPLA2/FABP4 |
| 5 | GO:0019216 | Regulation of lipid metabolic process | 1.38×10−4 | ACSL1/SCD/DGAT2/PNPLA2/LEP |
| 5 | GO:0035337 | Fatty-acyl-CoA metabolic process | 1.60×10−4 | ACSL1/SCD/DGAT2 |
| 6 | GO:0072329 | Monocarboxylic acid catabolic process | 2.81×10−4 | ABAT/EHHADH/ALDH3A2/PECR |
| 6 | GO:0006631 | Fatty acid metabolic process | 2.81×10−4 | PRKAR2B/EHHADH/ALDH3A2/PECR/PDHX |
| 6 | GO:0044282 | Small molecule catabolic process | 2.81×10−4 | ABAT/EHHADH/ALDH3A2/ALDH1B1/PECR |
| 6 | GO:0034308 | Primary alcohol metabolic process | 5.03×10−4 | ALDH3A2/ALDH1B1/PECR |
| 6 | GO:0016054 | Organic acid catabolic process | 8.48×10−4 | ABAT/EHHADH/ALDH3A2/PECR |
Only the top five terms are listed. GO, Gene Ontology.
Figure 5.Pathway and GO term enrichment of microRNAs. (A) Kyoto Encyclopedia of Genes and Genomes pathway and (B) GO term enrichment analyses for target genes of differentially expressed microRNAs. The values within brackets are the number of genes enriched. miR, microRNA; GO, Gene Ontology.
Kyoto Encyclopedia of Genes and Genomes pathway enrichment for target genes of microRNAs.
| Expression | Cluster | ID | Description | Adjusted P-value | Genes |
|---|---|---|---|---|---|
| Up | hsa-miR-103a-2-5p | hsa04921 | Oxytocin signaling pathway | 2.67×10−2 | NFATC2/OXTR/GUCY1A3/PTGS2 |
| hsa-miR-582-5p | hsa05167 | Kaposi's sarcoma-associated herpesvirus infection | 2.16×10−2 | PTGS2/ANGPT2/CXCL2/NFATC2 | |
| hsa-miR-642a-3p | hsa05202 | Transcriptional misregulation in cancer | 2.51×10−2 | NR4A3 | |
| hsa-miR-1292-5p | hsa04625 | C-type lectin receptor signaling pathway | 3.91×10−3 | PTGS2/IRF1 | |
| hsa-miR-1292-5p | hsa05165 | Human papillomavirus infection | 1.85×10−2 | PTGS2/IRF1 | |
| hsa-miR-1292-5p | hsa04923 | Regulation of lipolysis in adipocytes | 3.92×10−2 | PTGS2 | |
| hsa-miR-1292-5p | hsa04370 | VEGF signaling pathway | 3.92×10−2 | PTGS2 | |
| hsa-miR-1292-5p | hsa04917 | Prolactin signaling pathway | 3.92×10−2 | IRF1 | |
| hsa-miR-1292-5p | hsa05140 | Leishmaniasis | 3.92×10−2 | PTGS2 | |
| hsa-miR-1292-5p | hsa05133 | Pertussis | 3.92×10−2 | IRF1 | |
| hsa-miR-1292-5p | hsa04657 | IL-17 signaling pathway | 3.92×10−2 | PTGS2 | |
| hsa-miR-1292-5p | hsa04064 | NF-κB signaling pathway | 3.92×10−2 | PTGS2 | |
| hsa-miR-1292-5p | hsa04668 | TNF signaling pathway | 4.04×10−2 | PTGS2 | |
| hsa-miR-1292-5p | hsa05160 | Hepatitis C | 4.38×10−2 | IRF1 | |
| hsa-miR-30c-5p | hsa05161 | Hepatitis B | 2.34×10−2 | NFATC2/CCNA1/CCNE2 | |
| hsa-miR-30c-5p | hsa04218 | Cellular senescence | 2.34×10−2 | NFATC2/CCNA1/CCNE2 | |
| Down | hsa-miR-154-3p | hsa00561 | Glycerolipid metabolism | 5.15×10−3 | GPAM/ALDH1B1 |
| hsa-miR-154-3p | hsa00340 | Histidine metabolism | 3.86×10−2 | ALDH1B1 | |
| hsa-miR-154-3p | hsa00053 | Ascorbate and aldarate metabolism | 3.86×10−2 | ALDH1B1 | |
| hsa-miR-154-3p | hsa00410 | β-alanine metabolism | 3.86×10−2 | ALDH1B1 | |
| hsa-miR-154-3p | hsa00620 | Pyruvate metabolism | 3.86×10−2 | ALDH1B1 | |
| hsa-miR-25-5p | hsa04514 | Cell adhesion molecules (CAMs) | 5.22×10−4 | PTPRF/F11R/JAM2 | |
| hsa-miR-25-5p | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 4.44×10−3 | F11R/JAM2 | |
| hsa-miR-25-5p | hsa04670 | Leukocyte transendothelial migration | 8.00×10−3 | F11R/JAM2 | |
| hsa-miR-25-5p | hsa04530 | Tight junction | 1.37×10−2 | F11R/JAM2 | |
| hsa-miR-25-5p | hsa00340 | Histidine metabolism | 4.01×10−2 | ALDH1B1 | |
| hsa-miR-302d-3p | hsa04080 | Neuroactive ligand-receptor interaction | 1.35×10−2 | EDNRB/LEP/RXFP1/PTGFR | |
| hsa-miR-485-3p | hsa04514 | Cell adhesion molecules (CAMs) | 3.30×10−2 | PTPRF/NLGN4X | |
| hsa-miR-487a-3p | hsa00410 | β-alanine metabolism | 1.07×10−2 | ALDH1B1/EHHADH | |
| hsa-miR-487a-3p | hsa00380 | Tryptophan metabolism | 1.07×10−2 | ALDH1B1/EHHADH | |
| hsa-miR-487a-3p | hsa00071 | Fatty acid degradation | 1.07×10−2 | ALDH1B1/EHHADH | |
| hsa-miR-487a-3p | hsa00280 | Valine, leucine and isoleucine degradation | 1.07×10−2 | ALDH1B1/EHHADH | |
| hsa-miR-487a-3p | hsa00310 | Lysine degradation | 1.15×10−2 | ALDH1B1/EHHADH | |
| hsa-miR-487a-3p | hsa00561 | Glycerolipid metabolism | 1.15×10−2 | GPAM/ALDH1B1 | |
| hsa-miR-411-3p | hsa00061 | Fatty acid biosynthesis | 3.16×10−2 | OLAH | |
| hsa-miR-411-3p | hsa04623 | Cytosolic DNA-sensing pathway | 4.34×10−2 | CXCL10 | |
| hsa-miR-411-3p | hsa04622 | RIG-I-like receptor signaling pathway | 4.34×10−2 | CXCL10 | |
| hsa-miR-411-3p | hsa04657 | IL-17 signaling pathway | 4.34×10−2 | CXCL10 | |
| hsa-miR-411-3p | hsa04620 | Toll-like receptor signaling pathway | 4.34×10−2 | CXCL10 | |
| hsa-miR-411-3p | hsa04668 | TNF signaling pathway | 4.34×10−2 | CXCL10 |
miR, microRNA.
GO term enrichment for target genes of microRNAs.
| Expression | Cluster | ID | Description | Adjusted P-value | Genes |
|---|---|---|---|---|---|
| Up | hsa-miR-103a-2-5p | GO:0051968 | Positive regulation of synaptic transmission, glutamatergic | 1.18×10−2 | OXTR/NLGN1/PTGS2 |
| hsa-miR-103a-2-5p | GO:0048661 | Positive regulation of smooth muscle cell proliferation | 1.18×10−2 | IL10/NR4A3/IL6R/PTGS2 | |
| hsa-miR-103a-2-5p | GO:0050807 | Regulation of synapse organization | 2.79×10−2 | OXTR/IL10/NLGN1/ LRRTM2 | |
| hsa-miR-103a-2-5p | GO:0048660 | Regulation of smooth muscle cell proliferation | 2.79×10−2 | IL10/NR4A3/IL6R/PTGS2 | |
| hsa-miR-103a-2-5p | GO:0048659 | Smooth muscle cell proliferation | 2.79×10−2 | IL10/NR4A3/IL6R/PTGS2 | |
| hsa-miR-378a-5p | GO:0007162 | Negative regulation of cell adhesion | 3.27×10−3 | IRF1/PELI1/ANGPT2/IL10/SMAD7/SEMA3E | |
| hsa-miR-378a-5p | GO:0031589 | Cell-substrate adhesion | 6.55×10−3 | LIMS1/RAC2/KIF14/ANGPT2/SEMA3E/PEAK1 | |
| hsa-miR-378a-5p | GO:0050868 | Negative regulation of T cell activation | 8.67×10−3 | IRF1/PELI1/IL10/SMAD7 | |
| hsa-miR-378a-5p | GO:1903038 | Negative regulation of leukocyte cell-cell adhesion | 9.77×10−3 | IRF1/PELI1/IL10/SMAD7 | |
| hsa-miR-378a-5p | GO:0051250 | Negative regulation of lymphocyte activation | 1.53×10−2 | IRF1/PELI1/IL10/SMAD7 | |
| hsa-miR-582-3p | GO:1902043 | Positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | 6.49×10−3 | SKIL/TIMP3 | |
| hsa-miR-582-3p | GO:2001238 | Positive regulation of extrinsic apoptotic signaling pathway | 2.23×10−2 | SKIL/TIMP3 | |
| hsa-miR-582-3p | GO:1902041 | Regulation of extrinsic apoptotic signaling pathway via death domain receptors | 2.23×10−2 | SKIL/TIMP3 | |
| hsa-miR-582-3p | GO:0030512 | Negative regulation of transforming growth factor β receptor signaling pathway | 2.23×10−2 | SKIL/HTRA4 | |
| hsa-miR-582-3p | GO:1903845 | Negative regulation of cellular response to transforming growth factor β stimulus | 2.23×10−2 | SKIL/HTRA4 | |
| hsa-miR-642a-3p | GO:0048839 | Inner ear development | 4.66×10−2 | NR4A3/MCOLN3 | |
| hsa-miR-642a-3p | GO:0043583 | Ear development | 4.66×10−2 | NR4A3/MCOLN3 | |
| hsa-miR-642a-3p | GO:0061469 | Regulation of type B pancreatic cell proliferation | 4.66×10−2 | NR4A3 | |
| hsa-miR-642a-3p | GO:0061081 | Positive regulation of myeloid leukocyte cytokine production involved in immune response | 4.66×10−2 | NR4A3 | |
| hsa-miR-642a-3p | GO:0070486 | Leukocyte aggregation | 4.66×10−2 | NR4A3 | |
| hsa-miR-668-3p | GO:0051983 | Regulation of chromosome segregation | 1.74×10−2 | KIF2C/MKI67/GEN1 | |
| hsa-miR-345-5p | GO:0003188 | Heart valve formation | 3.30×10−2 | HEY2/ERG | |
| hsa-miR-345-5p | GO:0007265 | Ras protein signal transduction | 4.24×10−2 | CDC42EP2/NGFR/RASAL2/P2RY8 | |
| hsa-miR-345-5p | GO:0060317 | Cardiac epithelial to mesenchymal transition | 4.65×10−2 | HEY2/ERG | |
| hsa-miR-345-5p | GO:0003179 | Heart valve morphogenesis | 4.65×10−2 | HEY2/ERG | |
| hsa-miR-345-5p | GO:0007266 | Rho protein signal transduction | 4.65×10−2 | CDC42EP2/NGFR/P2RY8 | |
| hsa-miR-664a-3p | GO:0060712 | Spongiotrophoblast layer development | 3.57×10−3 | LIF/NRK/PHLDA2 | |
| hsa-miR-664a-3p | GO:0010976 | Positive regulation of neuron projection development | 3.11×10−2 | MAP1B/NTRK2/PAK3/SKIL/NLGN1 | |
| hsa-miR-664a-3p | GO:0033135 | Regulation of peptidyl-serine phosphorylation | 3.11×10−2 | LIF/PTGS2/NTRK2/RASSF2 | |
| hsa-miR-664a-3p | GO:0010770 | Positive regulation of cell morphogenesis involved in differentiation | 3.11×10−2 | MAP1B/NTRK2/PAK3/SKIL | |
| hsa-miR-664a-3p | GO:0010769 | Regulation of cell morphogenesis involved in differentiation | 3.11×10−2 | MAP1B/NTRK2/PAK3/SKIL/NLGN1 | |
| hsa-let-7e-5p | GO:0010866 | Regulation of triglyceride biosynthetic process | 5.26×10−3 | THRSP/DGAT2 | |
| hsa-let-7e-5p | GO:0046890 | Regulation of lipid biosynthetic process | 5.26×10−3 | THRSP/SCD/DGAT2 | |
| hsa-let-7e-5p | GO:0019432 | Triglyceride biosynthetic process | 5.26×10−3 | THRSP/DGAT2 | |
| hsa-let-7e-5p | GO:0090207 | Regulation of triglyceride metabolic process | 5.26×10−3 | THRSP/DGAT2 | |
| hsa-let-7e-5p | GO:0046460 | Neutral lipid biosynthetic process | 5.26×10−3 | THRSP/DGAT2 | |
| hsa-miR-212-3p | GO:0050708 | Regulation of protein | 5.15×10−3 | SLC2A1/IL1RL1/GPAM/PDE8B | |
| hsa-miR-212-3p | GO:0002791 | Regulation of peptide secretion | 5.15×10−3 | SLC2A1/IL1RL1/GPAM/PDE8B | |
| Down | hsa-miR-130b-5p | GO:0001101 | Response to acid chemical | 2.93×10−2 | WNT5A/ACSL1/LEP/PTGFR |
| hsa-miR-130b-5p | GO:0043032 | Positive regulation of macrophage activation | 2.93×10−2 | WNT5A/IL1RL1 | |
| hsa-miR-130b-5p | GO:0050727 | Regulation of inflammatory response | 3.66×10−2 | WNT5A/LEP/CX3CL1/IL1RL1 | |
| hsa-miR-130b-5p | GO:0072606 | Interleukin-8 secretion | 3.66×10−2 | WNT5A/LEP | |
| hsa-miR-130b-5p | GO:0001819 | Positive regulation of cytokine production | 3.66×10−2 | WNT5A/LEP/CX3CL1/IL1RL1 | |
| hsa-miR-23a-5p | GO:0006865 | Amino acid transport | 2.87×10−2 | LEP/SLC6A6/ATP1A2 | |
| hsa-miR-23a-5p | GO:0051955 | Regulation of amino acid transport | 2.87×10−2 | LEP/ATP1A2 | |
| hsa-miR-23a-5p | GO:0006109 | Regulation of carbohydrate metabolic process | 2.87×10−2 | LEP/IGFBP5/PFKFB4 | |
| hsa-miR-23a-5p | GO:0019229 | Regulation of vasoconstriction | 2.87×10−2 | LEP/ATP1A2 | |
| hsa-miR-23a-5p | GO:0046942 | Carboxylic acid transport | 2.87×10−2 | LEP/SLC6A6/ATP1A2 | |
| hsa-miR-23a-5p | GO:0001909 | Leukocyte mediated cytotoxicity | 3.30×10−2 | LEP/TREM1 | |
| hsa-miR-23a-5p | GO:0014897 | Striated muscle hypertrophy | 3.80×10−2 | LEP/IGFBP5 | |
| hsa-miR-23a-5p | GO:0010906 | Regulation of glucose metabolic process | 3.80×10−2 | LEP/IGFBP5 | |
| hsa-miR-23a-5p | GO:0010675 | Regulation of cellular carbohydrate metabolic process | 4.72×10−2 | LEP/IGFBP5 | |
| hsa-miR-23b-3p | GO:0007422 | Peripheral nervous system development | 4.39×10−2 | ALDH3A2/EDNRB/HOXD10 | |
| hsa-miR-302d-3p | GO:0010888 | Negative regulation of lipid storage | 3.41×10−2 | LEP/ABCG1 | |
| hsa-miR-302d-3p | GO:0032355 | Response to estradiol | 3.41×10−2 | LEP/TXNIP/PTGFR | |
| hsa-miR-302d-3p | GO:0008203 | Cholesterol metabolic process | 3.41×10−2 | VLDLR/LEP/ABCG1 | |
| hsa-miR-302d-3p | GO:1902652 | Secondary alcohol metabolic process | 3.41×10−2 | VLDLR/LEP/ABCG1 | |
| hsa-miR-302d-3p | GO:0006869 | Lipid transport | 3.41×10−2 | VLDLR/LEP/THRSP/ABCG1 | |
| hsa-miR-302d-3p | GO:1900015 | Regulation of cytokine production involved in inflammatory response | 3.41×10−2 | C5orf30/LEP | |
| hsa-miR-302d-3p | GO:0046890 | Regulation of lipid biosynthetic process | 3.41×10−2 | LEP/THRSP/ABCG1 | |
| hsa-miR-302d-3p | GO:0002534 | Cytokine production involved in inflammatory response | 3.41×10−2 | C5orf30/LEP | |
| hsa-miR-485-3p | GO:0035384 | Thioester biosynthetic process | 2.86×10−2 | PDHX/SCD | |
| hsa-miR-485-3p | GO:0071616 | Acyl-CoA biosynthetic process | 2.86×10−2 | PDHX/SCD |
GO, Gene Ontology; miR, microRNA.
Figure 6.ceRNA interaction network of lncRNA-miRNA-mRNAs in human adipose-derived stem cells. (A) Downregulated lncRNA-related ceRNA network; (B) upregulated lncRNA-related ceRNA network. Diamond nodes represent lncRNAs; triangle nodes represent miRNAs; oval nodes represent mRNAs. Edges represent the possible associations between lncRNAs, miRNAs and mRNAs. Pink, upregulated; light blue, downregulated. ceRNA, competing endogenous RNAs; lncRNA, long non-coding RNA; miRNA, microRNA.